Los puntos clave no están disponibles para este artículo en este momento.
Despite rapid advances in TB biosignature discovery, translation into usable diagnostics lags behind - especially for children and those with HIV. Studies often exclude these key populations, lack diverse validation, and depend on complex laboratory platforms. Bridging this gap requires early integration of feasibility, usability, and health system factors into product development. Multimodal, point-of-care tools adapted for low-resource settings and inclusive of high-risk children are essential. Implementation science and technology adaptation are critical to ensure real-world impact of these promising innovations.To summarize, non-sputum biosignatures offer an opportunity for early diagnosis of TB in children with HIV. However, these signatures need to be validated and be translated into affordable point-of-care tools that can be integrated with current diagnostic approaches and implemented in low resource settings.
Kitonsa et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: